Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: Role of gefitinib-induced down-regulation of thymidylate synthase

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Tsutomu Iwasa, Takeshi Yoshida, Erina Hatashita, Yuki Yamada, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI) in patients with advanced non-small cell lung cancer (NSCLC). The response rate to these drugs remains low, however, in NSCLC patients with wild-type EGFR alleles. Combination therapies with EGFR-TKIs and cytotoxic agents are considered a therapeutic option for patients with NSCLC expressing wild-type EGFR. We investigated the antiproliferative effect of the combination of the oral fluorouracil S-1 and the EGFR-TKI gefitinib in NSCLC cells of differing EGFR status. The combination of 5-fluorouracil and gefitinib showed a synergistic antiproliferative effect in vitro in all NSCLC cell lines tested. Combination chemotherapy with S-1 and gefitinib in vivo also had a synergistic antitumor effect on NSCLC xenografts regardless of the absence or presence of EGFR mutations. Gefitinib inhibited the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels. These observations suggest that gefitinib-induced down-regulation of thymidylate synthase is responsible, at least in part, for the synergistic antitumor effect of combined treatment with S-1 and gefitinib and provide a basis for clinical evaluation of combination chemotherapy with S-1 and EGFR-TKIs in patients with solid tumors.

Original languageEnglish
Pages (from-to)599-606
Number of pages8
JournalMolecular Cancer Therapeutics
Volume7
Issue number3
DOIs
Publication statusPublished - Mar 1 2008
Externally publishedYes

Fingerprint

Thymidylate Synthase
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Down-Regulation
Cell Line
Combination Drug Therapy
Fluorouracil
Protein-Tyrosine Kinases
E2F1 Transcription Factor
erbB-1 Genes
Mutation
gefitinib
Cytotoxins
Therapeutics
Heterografts
Alleles
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines : Role of gefitinib-induced down-regulation of thymidylate synthase. / Okabe, Takafumi; Okamoto, Isamu; Tsukioka, Sayaka; Uchida, Junji; Iwasa, Tsutomu; Yoshida, Takeshi; Hatashita, Erina; Yamada, Yuki; Satoh, Taroh; Tamura, Kenji; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Molecular Cancer Therapeutics, Vol. 7, No. 3, 01.03.2008, p. 599-606.

Research output: Contribution to journalArticle

Okabe, Takafumi ; Okamoto, Isamu ; Tsukioka, Sayaka ; Uchida, Junji ; Iwasa, Tsutomu ; Yoshida, Takeshi ; Hatashita, Erina ; Yamada, Yuki ; Satoh, Taroh ; Tamura, Kenji ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines : Role of gefitinib-induced down-regulation of thymidylate synthase. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 3. pp. 599-606.
@article{d2c392143f2540daa72432cd2e929253,
title = "Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: Role of gefitinib-induced down-regulation of thymidylate synthase",
abstract = "Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI) in patients with advanced non-small cell lung cancer (NSCLC). The response rate to these drugs remains low, however, in NSCLC patients with wild-type EGFR alleles. Combination therapies with EGFR-TKIs and cytotoxic agents are considered a therapeutic option for patients with NSCLC expressing wild-type EGFR. We investigated the antiproliferative effect of the combination of the oral fluorouracil S-1 and the EGFR-TKI gefitinib in NSCLC cells of differing EGFR status. The combination of 5-fluorouracil and gefitinib showed a synergistic antiproliferative effect in vitro in all NSCLC cell lines tested. Combination chemotherapy with S-1 and gefitinib in vivo also had a synergistic antitumor effect on NSCLC xenografts regardless of the absence or presence of EGFR mutations. Gefitinib inhibited the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels. These observations suggest that gefitinib-induced down-regulation of thymidylate synthase is responsible, at least in part, for the synergistic antitumor effect of combined treatment with S-1 and gefitinib and provide a basis for clinical evaluation of combination chemotherapy with S-1 and EGFR-TKIs in patients with solid tumors.",
author = "Takafumi Okabe and Isamu Okamoto and Sayaka Tsukioka and Junji Uchida and Tsutomu Iwasa and Takeshi Yoshida and Erina Hatashita and Yuki Yamada and Taroh Satoh and Kenji Tamura and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-07-0567",
language = "English",
volume = "7",
pages = "599--606",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines

T2 - Role of gefitinib-induced down-regulation of thymidylate synthase

AU - Okabe, Takafumi

AU - Okamoto, Isamu

AU - Tsukioka, Sayaka

AU - Uchida, Junji

AU - Iwasa, Tsutomu

AU - Yoshida, Takeshi

AU - Hatashita, Erina

AU - Yamada, Yuki

AU - Satoh, Taroh

AU - Tamura, Kenji

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI) in patients with advanced non-small cell lung cancer (NSCLC). The response rate to these drugs remains low, however, in NSCLC patients with wild-type EGFR alleles. Combination therapies with EGFR-TKIs and cytotoxic agents are considered a therapeutic option for patients with NSCLC expressing wild-type EGFR. We investigated the antiproliferative effect of the combination of the oral fluorouracil S-1 and the EGFR-TKI gefitinib in NSCLC cells of differing EGFR status. The combination of 5-fluorouracil and gefitinib showed a synergistic antiproliferative effect in vitro in all NSCLC cell lines tested. Combination chemotherapy with S-1 and gefitinib in vivo also had a synergistic antitumor effect on NSCLC xenografts regardless of the absence or presence of EGFR mutations. Gefitinib inhibited the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels. These observations suggest that gefitinib-induced down-regulation of thymidylate synthase is responsible, at least in part, for the synergistic antitumor effect of combined treatment with S-1 and gefitinib and provide a basis for clinical evaluation of combination chemotherapy with S-1 and EGFR-TKIs in patients with solid tumors.

AB - Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI) in patients with advanced non-small cell lung cancer (NSCLC). The response rate to these drugs remains low, however, in NSCLC patients with wild-type EGFR alleles. Combination therapies with EGFR-TKIs and cytotoxic agents are considered a therapeutic option for patients with NSCLC expressing wild-type EGFR. We investigated the antiproliferative effect of the combination of the oral fluorouracil S-1 and the EGFR-TKI gefitinib in NSCLC cells of differing EGFR status. The combination of 5-fluorouracil and gefitinib showed a synergistic antiproliferative effect in vitro in all NSCLC cell lines tested. Combination chemotherapy with S-1 and gefitinib in vivo also had a synergistic antitumor effect on NSCLC xenografts regardless of the absence or presence of EGFR mutations. Gefitinib inhibited the expression of the transcription factor E2F-1, resulting in the down-regulation of thymidylate synthase at the mRNA and protein levels. These observations suggest that gefitinib-induced down-regulation of thymidylate synthase is responsible, at least in part, for the synergistic antitumor effect of combined treatment with S-1 and gefitinib and provide a basis for clinical evaluation of combination chemotherapy with S-1 and EGFR-TKIs in patients with solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=41849136922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849136922&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-0567

DO - 10.1158/1535-7163.MCT-07-0567

M3 - Article

C2 - 18347146

AN - SCOPUS:41849136922

VL - 7

SP - 599

EP - 606

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -